相关实验视频
Updated: Jul 25, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
SIRT1激活剂E1231通过调节脂质代谢来缓解非酒精性脂肪性肝病
Jiangxue Han1, Shunwang Li1, Weizhi Wang1
1NHC Key Laboratory of Biotechnology of Antibiotics, National Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Tiantan Xili 1#, Beijing 100050, China.
一种新的化合物,E1231,激活SIRT1,有效地治疗小鼠的非酒精性脂肪性肝病 (NAFLD). 这种SIRT1激活剂减少了肝损伤和改善了脂质代谢,显示了NAFLD治疗的前景.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 非酒精性脂肪肝 (NAFLD) 是一种普遍存在的肝脏疾病.
- 赛尔图因1 (SIRT1) 在调节NAFLD相关的脂质和胆固醇代谢方面发挥着关键作用.
研究的目的:
- 研究一种新型SIRT1激活剂E1231,用于NAFLD的治疗潜力.
- 阐明E1231对NAFLD的影响背后的分子机制.
主要方法:
- 使用了一种高脂肪,高胆固醇饮食诱导的NAFLD小鼠模型.
- 小鼠通过口腔输液用E1231进行治疗.
- 进行了生物化学分析,组织学染色和西部斑点检查.
主要成果:
- E1231治疗改善了脂质不良症,降低了肝酶 (ALT,AST) 和降低了肝脂含量.
- E1231治疗降低了肝肥胖症和NAFLD活动评分 (NAS).
- E1231调节了脂质代谢中的关键蛋白质,包括增加SIRT1,PGC-1α和p-AMPKα,同时减少ACC和SCD-1.
结论:
- 作为SIRT1激活剂的E1231,有效地减轻高脂肪,高胆固醇饮食引起的NAFLD.
- 治疗效果涉及SIRT1-AMPKα通路,改善肝损伤和脂质代谢.
- E1231是NAFLD治疗的潜在治疗候选者.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:35A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
相关概念视频
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipid Catabolism
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Regulation of Metabolism